A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia.
The Fc fusion technology has been introduced to generate long-acting antagonistic drugs such as Enbrel, Orencia and Amevive. Here, Genexine created a novel noncytolytic hybrid Fc (hyFc) as a carrier of agonistic protein drugs using naturally existing IgD and IgG4 Fcs without any mutation in the hyFc region. The erythropoietin (EPO) fused with hyFc exhibited little binding activity to FcγR and C1q molecules that are main mediators for death of target cells. The EPO-hyFc showed higher in vitro and in vivo bioactivities than EPOIgG1 Fc and highly glycosylated EPO (Aranesp). Phase I clinical trial with EPO-hyFc is currently undergoing in Korea.
Genexine Co., Korea Bio Park, Seongnam, Korea. shyang@genexine.com
Se Hwan
SH
Yang
Sang In
SI
Yang
Yo-Kyung
YK
Chung
D000077944:Alefacept; D000740:Anemia / Q000188:drug therapy*; D000818:Animals; D000068256:Darbepoetin alfa; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000378:metabolism; D004921:Erythropoietin / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000235:genetics / Q000378:metabolism; D006801:Humans; D011485:Protein Binding / Q000235:genetics; D011961:Receptors, Fc / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D014961:X-Ray Diffraction
D003692:Delayed-Action Preparations; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000077944:Alefacept